<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006300.pub4" GROUP_ID="CHILDCA" ID="145805122110271178" MERGED_FROM="" MODIFIED="2015-09-29 14:50:30 +0100" MODIFIED_BY="Jos Noorman" REVIEW_NO="004" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2015-09-29 14:50:30 +0100" MODIFIED_BY="Jos Noorman">
<TITLE MODIFIED="2009-10-19 13:26:00 +0200" MODIFIED_BY="Elvira van Dalen">Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients</TITLE>
<CONTACT MODIFIED="2015-09-29 14:50:30 +0100" MODIFIED_BY="Jos Noorman"><PERSON ID="D0402DB382E26AA2012E60F38D3AC37D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Renée</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Mulder</LAST_NAME><EMAIL_1>r.l.mulder@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>P.O. Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 20 5665419</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-09-29 14:50:30 +0100" MODIFIED_BY="Jos Noorman"><PERSON ID="D0402DB382E26AA2012E60F38D3AC37D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Renée</FIRST_NAME><MIDDLE_INITIALS>L</MIDDLE_INITIALS><LAST_NAME>Mulder</LAST_NAME><EMAIL_1>r.l.mulder@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>P.O. Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+ 31 20 5665419</PHONE_1></ADDRESS></PERSON><PERSON ID="A9ABB2A482E26AA201BA4B54736E743F" ROLE="AUTHOR"><FIRST_NAME>Marios</FIRST_NAME><LAST_NAME>Paulides</LAST_NAME><POSITION>Referent</POSITION><ADDRESS><ORGANISATION>Drug Commission of the German Medical Association</ORGANISATION><ADDRESS_1>Herbert-Lewin-Platz 1</ADDRESS_1><CITY>Berlin</CITY><ZIP>10623</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS><FOOTNOTE>Joint first authorship with Renée L Mulder</FOOTNOTE></PERSON><PERSON ID="B00C074F82E26AA200D5E26BC336DF91" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Thorsten</FIRST_NAME><LAST_NAME>Langer</LAST_NAME><POSITION>Professor</POSITION><EMAIL_1>thorsten.langer@uksh.de</EMAIL_1><EMAIL_2>tnlanger@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Pediatric Oncology Hematology</DEPARTMENT><ORGANISATION>University Hospital for Children and Adolescents</ORGANISATION><ADDRESS_1>Ratzeburger Allee 160</ADDRESS_1><CITY>Lübeck</CITY><ZIP>23538</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>++49 451 500 2045</PHONE_1><FAX_1>++49 451 500 3767</FAX_1></ADDRESS></PERSON><PERSON ID="13704" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Leontien</FIRST_NAME><MIDDLE_INITIALS>CM</MIDDLE_INITIALS><LAST_NAME>Kremer</LAST_NAME><EMAIL_1>l.c.kremer@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5667132</PHONE_1></ADDRESS></PERSON><PERSON ID="13729" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Elvira</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>van Dalen</LAST_NAME><EMAIL_1>e.c.vandalen@amc.uva.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Paediatric Oncology</DEPARTMENT><ORGANISATION>Emma Children's Hospital/Academic Medical Center</ORGANISATION><ADDRESS_1>PO Box 22660 (room TKsO-247)</ADDRESS_1><CITY>Amsterdam</CITY><ZIP>1100 DD</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 20 5665697</PHONE_1><FAX_1>+ 31 20 5669021</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-08-22 08:34:36 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="3" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="3" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-09-29 15:06:14 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-09-29 15:06:14 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="8" YEAR="2015"/>
<DESCRIPTION>
<P>No new studies were identified during the update. The conclusions have thus not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-06-08 16:00:44 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="3" YEAR="2015"/>
<DESCRIPTION>
<P>The search for eligible studies was updated to March 2015</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-09-29 15:48:42 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-09-29 15:48:42 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>No new studies could be included in the review. As a result the conclusions have not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-29 14:53:54 +0100" MODIFIED_BY="Jos Noorman">
<DATE DAY="13" MONTH="9" YEAR="2012"/>
<DESCRIPTION>
<P>The search for eligible studies was updated to March 2012. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-08-24 14:46:32 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2009-08-24 14:46:32 +0200" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>Foundation of Pediatric Cancer Research (SKK) Amsterdam</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-08-24 14:46:32 +0200" MODIFIED_BY="[Empty name]">
<NAME>Stichting Kinderen Kankervrij (KIKA)</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-09-29 15:16:19 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-09-29 15:07:30 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-08-31 11:26:51 +0200" MODIFIED_BY="[Empty name]">Cyclophosphamide compared to ifosfamide for the treatment of sarcoma in children and young adults</TITLE>
<SUMMARY_BODY MODIFIED="2015-09-29 15:07:30 +0200" MODIFIED_BY="[Empty name]">
<P>Sarcomas are tumours that arise from bone and soft tissues. They can occur in all ages. As a result of the introduction of polychemotherapy, the survival of children and young adults with different types of sarcoma has improved dramatically. Alkylating agents, such as cyclophosphamide and ifosfamide, have played a major role in this improvement. However, in the literature there is still no consensus as to which chemotherapeutic agent is more effective. A well-informed decision on the use of cyclophosphamide and ifosfamide in the treatment of children and young adults diagnosed with a sarcoma should be based on high-quality evidence on both anti-tumour efficacy and adverse effects.</P>
<P>This systematic review focused on (ideally randomised) controlled studies. We found that there were no such studies comparing cyclophosphamide and ifosfamide in paediatric and young adult sarcoma patients. More high-quality research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-09-29 15:13:18 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-08-24 13:29:19 +0200" MODIFIED_BY="[Empty name]">
<P>Alkylating agents, such as cyclophosphamide and ifosfamide, play a major role in the improved survival of children and young adults with bone and soft tissue sarcoma. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse effects. This is the second update of the first systematic review evaluating the state of evidence on the effectiveness of cyclophosphamide as compared to ifosfamide for paediatric and young adult patients with sarcoma.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-09-29 15:13:18 +0200" MODIFIED_BY="[Empty name]">
<P>The primary obective was to compare the effectiveness, that is response rate, event-free survival and overall survival, of cyclophosphamide with that of ifosfamide for paediatric and young adult patients with sarcoma. Secondary objectives were to determine effects of these agents on toxicities (including late effects) and quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-09-29 15:07:09 +0200" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (<I>The Cochrane Library</I> 2015, issue 2), MEDLINE/PubMed (from 1966 to March 2015) and EMBASE/Ovid (from 1980 to March 2015) with prespecified terms. In addition, we searched reference lists of relevant articles, conference proceedings and ongoing trial databases (www.controlled-trials.com; searched June 2015).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-09-03 13:26:10 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing cyclophosphamide and ifosfamide for the treatment of different types of sarcoma in paediatric and young adult patients (aged less than 30 years at diagnosis). Chemotherapy other than either cyclophosphamide or ifosfamide should have been the same in both treatment groups.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-12-01 15:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently performed the study selection.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-31 11:15:44 +0200" MODIFIED_BY="[Empty name]">
<P>No studies meeting the inclusion criteria of the review were identified.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-09-29 15:07:20 +0200" MODIFIED_BY="[Empty name]">
<P>No RCTs or CCTs comparing the effectiveness of cyclophosphamide and ifosfamide in the treatment of bone and soft tissue sarcoma in children and young adults were identified. Therefore no definitive conclusions can be made about the effects of cyclophosphamide and ifosfamide in these patients. Based on the currently available evidence, we are not able to give recommendations for clinical practice. More high-quality research is needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-09-29 15:15:42 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-09-29 15:09:10 +0200" MODIFIED_BY="[Empty name]">
<P>Sarcomas are mesenchymal tumours that arise from bone and soft tissues. They can occur in people of all ages (<LINK REF="REF-Kasper-2005" TYPE="REFERENCE">Kasper 2005</LINK>). The German Childhood Cancer Registry (<LINK REF="REF-GCCR-2004" TYPE="REFERENCE">GCCR 2004</LINK>; <LINK REF="REF-GCCR-2004-appendix" TYPE="REFERENCE">GCCR 2004 appendix</LINK>) describes incidence rates of 3.7% for rhabdomyosarcoma, which is the most common form of soft tissue sarcoma in childhood and adolescence (<LINK REF="STD-Stevens-2005" TYPE="STUDY">Stevens 2005</LINK>), 2.3% for osteosarcoma and 2.1% for Ewing's sarcoma.</P>
<P>Although the prognosis of the different types of sarcomas in children still depends on several prognostic factors, such as the presence of metastases, tumour volume and primary tumour site, it has been improving since the introduction of polychemotherapy. For example the cure rate for rhabdomyosarcoma has changed from 25% in 1970 to 70% in 1991 (<LINK REF="STD-Crist-2001" TYPE="STUDY">Crist 2001</LINK>). Alkylating agents, such as the oxazaphosphorines ifosfamide and cyclophosphamide, have played a major role in this improvement.</P>
<P>Cyclophosphamide is a widely employed cytotoxic agent and is also used against childhood sarcomas as it has shown good anti-tumour efficacy in these malignancies (<LINK REF="REF-Spunt-2004" TYPE="REFERENCE">Spunt 2004</LINK>; <LINK REF="REF-Lai-2005" TYPE="REFERENCE">Lai 2005</LINK>; <LINK REF="REF-Weller-2005" TYPE="REFERENCE">Weller 2005</LINK>). Its anti-tumour efficacy unfolds after metabolic activation and is the result of direct alkylation of target cell DNA leading to inter- and intra-strand cross-linking, which ultimately induces apoptosis in non-resistant cells. It also augments the efficacy of anti-tumour immune response and acts in an anti-angiogenic capacity by destroying circulating endothelial progenitor cells (<LINK REF="REF-Zhang-2005" TYPE="REFERENCE">Zhang 2005</LINK>). Since the early 1980s, its structural analogue ifosfamide has been increasingly substituted in its place for the treatment of childhood sarcomas (<LINK REF="REF-Paulussen-2001" TYPE="REFERENCE">Paulussen 2001</LINK>).</P>
<P>However, there is still controversy as to the comparative anti-tumour efficacy of these agents (<LINK REF="REF-Shaw-1990" TYPE="REFERENCE">Shaw 1990</LINK>; <LINK REF="REF-Carli-2003" TYPE="REFERENCE">Carli 2003</LINK>). Differences in toxicity profile (such as neurotoxicity, nephrotoxicity, myelotoxicity) are also important (<LINK REF="REF-Knijnenburg-2013" TYPE="REFERENCE">Knijnenburg 2013</LINK>). Especially relevant in paediatric oncology are the different late effects of these agents, with ifosfamide inducing, for example, severe tubulopathies up to the full Fanconi syndrome (<LINK REF="REF-Skinner-2003" TYPE="REFERENCE">Skinner 2003</LINK>), which has the potential to induce growth impairments in the children affected by it after cancer treatment (<LINK REF="REF-St_x00f6_hr-2007" TYPE="REFERENCE">Stöhr 2007</LINK>). This is not observed with cyclophosphamide (<LINK REF="REF-Rossi-1999" TYPE="REFERENCE">Rossi 1999</LINK>). Also important is the gonadotoxic potential of cyclophosphamide and ifosfamide (<LINK REF="REF-Howell-2001" TYPE="REFERENCE">Howell 2001</LINK>; <LINK REF="REF-Fawaz-2005" TYPE="REFERENCE">Fawaz 2005</LINK>), as are the possible cardiotoxic effects (<LINK REF="REF-Simbre-2005" TYPE="REFERENCE">Simbre 2005</LINK>).</P>
<P>This is the second update of the first systematic review evaluating the state of evidence on the anti-tumour efficacy and possible adverse effects of cyclophosphamide as compared to ifosfamide for paediatric and young adult patients with a bone or soft tissue sarcoma (<LINK REF="REF-Mulder-2010" TYPE="REFERENCE">Mulder 2010</LINK>; <LINK REF="REF-Mulder-2012" TYPE="REFERENCE">Mulder 2012</LINK>).</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-09-29 15:09:16 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Primary objective</HEADING>
<P>To compare the effectiveness of cyclophosphamide with that of ifosfamide for paediatric and young adult patients with sarcoma.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Secondary objectives</HEADING>
<P>To determine effects of these agents on toxicities (including late effects) and quality of life.</P>
</SUBSECTION>
</OBJECTIVES>
<METHODS MODIFIED="2015-09-29 15:13:40 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-09-29 15:13:40 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-12-01 15:53:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs). If no RCTs were identified we planned to include controlled clinical trials (CCTs). A CCT is a study that compares one or more intervention groups to one or more control groups (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-09-29 15:13:40 +0200" MODIFIED_BY="[Empty name]">
<P>Paediatric and young adult patients (&lt; 30 years of age at diagnosis) with soft tissue sarcoma, osteosarcoma or Ewing's sarcoma of all stages.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-12-01 15:54:11 +0100" MODIFIED_BY="[Empty name]">
<P>Patients should have received either cyclophosphamide or ifosfamide as part of their treatment. However, differences in the dosage and duration of administration of cyclophosphamide and ifosfamide were allowed. Chemotherapy, other than either cyclophosphamide or ifosfamide, should have been the same in both treatment groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-12-01 15:54:25 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-12-01 15:54:22 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Response rate (defined as the number of patients with a complete or partial remission).</LI>
<LI>Event-free survival (defined as the time to recurrence or progression of disease).</LI>
<LI>Overall patient survival (defined as the time to death from any cause).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-12-01 15:54:25 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Toxicities including late effects of treatment, in particular gonadotoxicity, nephrotoxicity, urotoxicity, neurotoxicity and cardiotoxicity.</LI>
<LI>Quality of life.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-08-24 14:37:34 +0200" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I>, 2015, issue 2), MEDLINE/PubMed (from 1966 to March 2015) and EMBASE/Ovid (from 1980 to March 2015).</P>
<P>The search strategies for the different electronic databases are shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
<P>We located information about trials not registered in CENTRAL, MEDLINE or EMBASE, either published or unpublished, by searching the reference lists of relevant articles and review articles. We also scanned the conference proceedings of the Sarcoma Meeting Stuttgart (SMS) (2005) and the Société Internationale d' Oncologie Pédiatrique (SIOP) (2003 to 2014), if available electronically and otherwise by handsearching. We searched for ongoing trials by scanning the ISRCTN register and the National Institute of Health register (<A HREF="http://www.controlled-trials.com">www.controlled-trials.com</A>; June 2015). We imposed no language restriction.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-12-01 16:02:54 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-12-01 16:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>After employing the search strategy described previously, two authors independently undertook identification of studies meeting the inclusion criteria. Discrepancies between authors were resolved by consensus. No third party arbitration was needed. We obtained any study seemingly meeting the inclusion criteria on the grounds of the title, abstract, or both in full for closer inspection. We clearly stated details of reasons for exclusion of any study considered for review.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-12-01 16:02:31 +0100" MODIFIED_BY="[Empty name]">
<P>Since no eligible studies were identified, data extraction by two independent authors using a standardised form could not be performed.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-12-01 16:02:54 +0100" MODIFIED_BY="[Empty name]">
<P>If eligible studies had been identified, two independent authors would have assessed the risk of bias in these studies according to the criteria of the Cochrane Childhood Cancer Group (<A HREF="http://ccg.cochrane.org/">http://ccg.cochrane.org/</A>). However, since no eligible studies were identified the assessment of risk of bias was not applicable.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-11-25 14:03:39 +0100" MODIFIED_BY="Jenny Bellorini">
<P>No eligible studies were identified. As a result, data analyses could not be performed.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-09-29 15:15:06 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-09-29 15:15:06 +0200" MODIFIED_BY="[Empty name]">
<P>After performing the searches of the electronic databases of CENTRAL, MEDLINE/PubMed and EMBASE/Ovid (in November 2008) we identified 724 references. Following initial screening of the titles, abstracts, or both we excluded 714 references which clearly did not meet all criteria for considering studies for this review. We obtained 10 articles in full. However, these studies were not eligible for inclusion in this review (see the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for the exact reasons).</P>
<P>Running the searches for the update in CENTRAL, MEDLINE/PubMed and EMBASE/Ovid (in March 2012) yielded a total of 161 new references. Following screening of the titles, abstracts, or both we excluded 160 references which clearly did not meet all inclusion criteria for this review. We obtained 1 article in full. However, this study was not eligible for inclusion in this review (<LINK REF="STD-Paulussen-2008" TYPE="STUDY">Paulussen 2008</LINK>; see the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for the exact reason).</P>
<P>Running the searches for the second update in CENTRAL, MEDLINE/PubMed and EMBASE/Ovid (in March 2015) yielded a total of 107 new references. Following screening of the titles, abstracts, or both we excluded 104 references which clearly did not meet all inclusion criteria for this review. We obtained 3 articles in full. However, these studies were not eligible for inclusion in this review (<LINK REF="STD-Gaspar-2012" TYPE="STUDY">Gaspar 2012</LINK>; <LINK REF="STD-Gupta-2012" TYPE="STUDY">Gupta 2012</LINK>; <LINK REF="STD-Le-Deley-2014" TYPE="STUDY">Le Deley 2014</LINK>; see the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table for the exact reason).</P>
<P>Scanning the reference lists of relevant studies and reviews and scanning the conference proceedings of the Sarcoma Meeting Stuttgart (SMS) and Société Internationale d' Oncologie Pédiatrique (SIOP) did identify six possibly eligible studies, which we obtained in full. Three of these studies were identified during the original review (2008) and the other three during the second update (2015); no studies were identified during the first (2012) update. None of the six studies were eligible for inclusion in this review and they were added to the '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' table. Scanning the ongoing trials databases did not identify any eligible ongoing studies.</P>
<P>In summary, our search did not identify any eligible RCTs or CCTs evaluating cyclophosphamide versus ifosfamide in paediatric and young adult sarcoma patients, in which chemotherapy other than either cyclophosphamide or ifosfamide was the same in both treatment groups.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-08-24 15:21:06 +0200" MODIFIED_BY="[Empty name]">
<P>Since no eligible studies were identified, the assessment of the risk of bias in included studies is not applicable.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-08-14 17:19:24 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Anti-tumour efficacy</HEADING>
<P>Since no eligible studies were identified, the comparative anti-tumour efficacy of cyclophosphamide versus ifosfamide for the treatment of sarcoma in children and young adults remains unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Toxicities and quality of life</HEADING>
<P>Since no eligible studies were identified, toxicities and quality of life associated with cyclophosphamide versus ifosfamide for the treatment of sarcoma in children and young adults remain unclear.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-09-29 15:15:18 +0200" MODIFIED_BY="[Empty name]">
<P>As a result of the introduction of polychemotherapy, the survival of children with different types of sarcoma has greatly improved. Alkylating agents, such as cyclophosphamide and ifosfamide, have played a major role in this improvement. However, there is still controversy as to their comparative anti-tumour efficacy and possible adverse effects. This is the second update of the first systematic review evaluating the current state of evidence on the effectiveness of cyclophosphamide versus ifosfamide in the treatment of paediatric and young adult patients with bone or soft tissue sarcoma (<LINK REF="REF-Mulder-2010" TYPE="REFERENCE">Mulder 2010</LINK>; <LINK REF="REF-Mulder-2012" TYPE="REFERENCE">Mulder 2012</LINK>).</P>
<P>To evaluate the effectiveness of cyclophosphamide versus ifosfamide in the treatment of sarcoma adequately the best study design is a randomised controlled trial (RCT) in which the only difference between the intervention and control group is the use of cyclophosphamide and ifosfamide. Unfortunately, we could not identify any such study. We were also unable to identify any eligible controlled clinical trials (CCTs). We did identify a RCT in which patients with non-metastatic rhabdomyosarcoma, aged less than 21 years, were randomised to either cyclophosphamide (2.2 g/m<SUP>2</SUP> for one day per cycle) or ifosfamide (1.8 g/m<SUP>2</SUP>/d for five days) (<LINK REF="STD-Crist-2001" TYPE="STUDY">Crist 2001</LINK>; <LINK REF="STD-Gupta-2012" TYPE="STUDY">Gupta 2012</LINK>). However, during continuation therapy all patients received cyclophosphamide. This was done to limit the cumulative ifosfamide dose and its potential nephrotoxic effects (<LINK REF="REF-Raney-1994" TYPE="REFERENCE">Raney 1994</LINK>). As a result, only data obtained prior to the time point where all patients received cyclophosphamide are eligible to answer the question of this review, but unfortunately these data are not available. Also, even if these data had been available, the eligible follow-up period was short (28 weeks), so only results for short-term outcomes would have been available.</P>
<P>It should be noted that in this systematic review RCTs and CCTs including both children and adults were only eligible for inclusion if the maximal age of the participants did not exceed 30 years or if data were presented separately for patients aged less than 30 years. There is some evidence on anti-tumour efficacy and adverse effects of treatment with cyclophosphamide as compared to treatment with ifosfamide from studies including both children and adults. In an RCT by Bramwell et al (<LINK REF="STD-Bramwell-1993" TYPE="STUDY">Bramwell 1993</LINK>), patients (eligible for inclusion if, among other things, aged 15 to 75 years) with advanced soft tissue sarcomas received either cyclophosphamide 1.5 g/m<SUP>2</SUP> (n = 68) or ifosfamide 5 g/m<SUP>2</SUP> (n = 67). Overall response rate (defined as complete or partial remission), although not significantly different between both treatment groups, was higher in patients treated with ifosfamide (i.e. 18% in patients treated with ifosfamide versus 7.5% in patients treated with cyclophosphamide; P = 0.13). Responses were mainly observed in synovial sarcomas, mixed mesodermal sarcomas and fibrosarcomas. The reason that no significant difference in overall response rate between the treatment groups was identified could be the fact that the number of patients in this study was too small (i.e. low power). Leukopenia was significantly greater in patients treated with cyclophosphamide, whereas nausea/vomiting was significantly worse in patients treated with ifosfamide. Other adverse effects did not differ significantly between both treatment groups.</P>
<P>However, extrapolation of these data to children is risky. The aetiology of malignancies in children and adults seems to be different (<LINK REF="REF-Burke-1999" TYPE="REFERENCE">Burke 1999</LINK>; <LINK REF="REF-Van-den-Berg-2002" TYPE="REFERENCE">Van den Berg 2002</LINK>). Also, pharmacokinetics and pharmacodynamics of many drugs vary with age, and their beneficial and adverse effects may be different in adults and children (<LINK REF="REF-Burke-1999" TYPE="REFERENCE">Burke 1999</LINK>; <LINK REF="REF-Groninger-2004" TYPE="REFERENCE">Groninger 2004</LINK>). High-quality RCTs in children with different types of sarcoma are therefore needed.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-09-29 15:15:42 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-09-29 15:15:36 +0200" MODIFIED_BY="[Empty name]">
<P>Since no randomised controlled trials (RCTs) or controlled clinical trials (CCTs) comparing cyclophosphamide and ifosfamide in paediatric and young adult sarcoma patients are available, no definitive conclusions can be made about their anti-tumour efficacy, toxicity and effects on quality of life. Based on the currently available evidence, we are not able to give recommendations for clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-09-29 15:15:42 +0200" MODIFIED_BY="[Empty name]">
<P>We identified no RCTs or CCTs comparing cyclophosphamide and ifosfamide in paediatric and young adult sarcoma patients. Before conclusions can be made about their anti-tumour efficacy, toxicity and effects on quality of life, more research is needed. However, before a decision can be made as to whether new RCTs comparing cyclophosphamide and ifosfamide in paediatric and young adult sarcoma patients are necessary, evidence in adults should be evaluated in a systematic manner, keeping in mind the fact that it is risky to extrapolate adult data to children.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-09-29 15:15:53 +0200" MODIFIED_BY="[Empty name]">
<P>Leontien Kremer and Elvira van Dalen, the Co-ordinating Editors of the Childhood Cancer Group, are co-authors of this review and therefore they could not act as the Co-ordinating Editors for this review. Wim J Tissing (Department of Pediatric Oncology/Hematology, Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands) was willing to take on this task, for which we thank him. Also, we thank Edith Leclercq, the Trials Search Co-ordinator of the Childhood Cancer Group, for running the search strategy in the different databases and providing us with the titles and abstracts of the searches, and Wolfgang Stöhr for his help in preparing the protocol for this review. The editorial base of the Cochrane Childhood Cancer Group is funded by Kinderen Kankervrij (KIKA).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-09-29 15:16:19 +0200" MODIFIED_BY="[Empty name]">
<P>Renée L Mulder assessed studies against the inclusion criteria. She searched for unpublished and ongoing studies. She contributed to the interpretation of the results. She wrote and revised the review.</P>
<P>Marios Paulides designed the review and wrote the protocol. He assessed studies against the inclusion criteria. He contributed to the interpretation of the results. He critically reviewed the review.</P>
<P>Thorsten Langer critically reviewed the protocol. He contributed to the interpretation of the results. He critically reviewed the review.</P>
<P>Leontien CM Kremer designed the review and critically reviewed the protocol. She contributed to the interpretation of the results. She critically reviewed the review.</P>
<P>Elvira C van Dalen designed the review and wrote the protocol. She developed the search strategy. She assessed studies against the inclusion criteria. She searched for unpublished and ongoing studies. She interpreted the results. She wrote and revised the review.</P>
<P>All authors approved the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-24 15:01:48 +0200" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-09-29 15:18:47 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-09-29 15:18:47 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES MODIFIED="2015-09-29 15:18:47 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Baker-2000" MODIFIED="2009-08-24 13:09:06 +0200" MODIFIED_BY="[Empty name]" NAME="Baker 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-08-24 13:08:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baker KS, Anderson JR, Link MP, Grier HE, Qualman SJ, Maurer HM, et al</AU>
<TI>Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2000</YR>
<VL>18</VL>
<NO>12</NO>
<PG>2427-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bramwell-1986" MODIFIED="2009-12-01 16:13:19 +0100" MODIFIED_BY="[Empty name]" NAME="Bramwell 1986" YEAR="1986">
<REFERENCE MODIFIED="2009-12-01 16:13:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Thomas D, et al</AU>
<TI>Cyclophosphamide versus ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1986</YR>
<VL>18</VL>
<NO>Suppl 2</NO>
<PG>S13-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bramwell-1987" MODIFIED="2009-12-01 16:13:38 +0100" MODIFIED_BY="[Empty name]" NAME="Bramwell 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-12-01 16:13:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, et al</AU>
<TI>Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas</TI>
<SO>European Journal of Cancer &amp; Clinical Oncology</SO>
<YR>1987</YR>
<VL>23</VL>
<NO>3</NO>
<PG>311-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bramwell-1993" MODIFIED="2009-12-01 16:13:54 +0100" MODIFIED_BY="[Empty name]" NAME="Bramwell 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-12-01 16:13:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verweij J, et al</AU>
<TI>Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer (EORTC), Soft Tissue and Bone Sarcoma Group</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1993</YR>
<VL>31</VL>
<NO>Suppl 2</NO>
<PG>S180-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crist-1999" MODIFIED="2015-08-26 09:48:13 +0200" MODIFIED_BY="[Empty name]" NAME="Crist 1999" YEAR="1999">
<REFERENCE MODIFIED="2015-08-26 09:48:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Crist W, Anderson J, Maurer H, Wiener E, Donaldson S, Qualman S</AU>
<TI>Preliminary results for patients with local/regional tumors treated on the intergroup rhabdomyosarcoma study-IV (1991-97)</TI>
<SO>ASCO Annual Meeting</SO>
<YR>1999</YR>
<PG>[abstract 2141]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crist-2001" MODIFIED="2009-12-01 16:15:38 +0100" MODIFIED_BY="[Empty name]" NAME="Crist 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-12-01 16:15:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, et al</AU>
<TI>Intergroup rhabdomyosarcoma study - IV: results for patients with nonmetastatic disease</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>12</NO>
<PG>3091-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dirksen-2012" MODIFIED="2015-09-29 15:18:05 +0200" MODIFIED_BY="[Empty name]" NAME="Dirksen 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-29 15:18:05 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dirksen U, Ranft A, Le Deley MC, Whelan J, Paulussen M, Oberlin O, et al</AU>
<TI>Comparison of Cyclophosphamide versus Ifosfamide containing adjuvant chemotherapy (CTX) in Ewing sarcoma (ES) patients: results of the randomized standard risk (SR) cohort of EUROE.-E.W.I.N.G. 99 Trial</TI>
<SO>Journal of Cancer Research and Clinical Oncology</SO>
<YR>2012</YR>
<VL>138</VL>
<NO>Suppl 1</NO>
<PG>16 [abstract B31-0218]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dirksen-2013" MODIFIED="2015-06-18 15:20:46 +0200" MODIFIED_BY="[Empty name]" NAME="Dirksen 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-06-18 15:20:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dirksen U, van den Berg H, Le Delay M, Whelan J, Oberlin O, Paulussen M, et al</AU>
<TI>Impact of gender on efficacy of alkylating agents and their acute toxicity in patients with standard risk localized ewing sarcomas (EWS) in the EURO-EWING99-(EE99)-R1 trial</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2013</YR>
<VL>60</VL>
<PG>26 [abstract O-0093]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunst-1998" MODIFIED="2009-08-25 13:13:44 +0200" MODIFIED_BY="[Empty name]" NAME="Dunst 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-08-25 13:13:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunst J, Ahrens S, Paulussen M, Rübe C, Winkelmann W, Zoubek A, et al</AU>
<TI>Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>1998</YR>
<VL>42</VL>
<NO>2</NO>
<PG>379-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gaspar-2012" MODIFIED="2015-09-29 15:18:30 +0200" MODIFIED_BY="[Empty name]" NAME="Gaspar 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-09-29 15:18:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gaspar N, Rey A, Bérard PM, Michon J, Gentet JC, Tabone MD, et al</AU>
<TI>Risk adapted chemotherapy for localised Ewing's sarcoma of bone: the French EW93 study</TI>
<SO>European Journal of Cancer</SO>
<YR>2012</YR>
<VL>48</VL>
<PG>1376-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gupta-2012" MODIFIED="2015-08-24 14:40:17 +0200" MODIFIED_BY="[Empty name]" NAME="Gupta 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-08-24 14:40:17 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gupta AA, Anderson JR, Pappo AS, Spunt SL, Dasgupta R, Indelicato DJ, et al</AU>
<TI>Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee</TI>
<SO>Cancer</SO>
<YR>2012</YR>
<VL>118</VL>
<PG>1130-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jurgens-2000" MODIFIED="2015-08-26 09:56:58 +0200" MODIFIED_BY="[Empty name]" NAME="Jurgens 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-08-26 09:56:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jurgens H, Ahrens S, Frohlich B, Paulussen M, Zoubek A, Lewis I, et al</AU>
<TI>European Intergroup Cooperative Ewing's Sarcoma Study (EICESS92): first results</TI>
<SO>ASCO Annual Meeting</SO>
<YR>2000</YR>
<PG>[abstract 2286]</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Deley-2014" MODIFIED="2015-09-29 15:18:47 +0200" MODIFIED_BY="[Empty name]" NAME="Le Deley 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-09-29 15:18:47 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, et al</AU>
<TI>Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2014</YR>
<VL>32</VL>
<PG>2440-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paulussen-1999" MODIFIED="2009-12-01 16:16:08 +0100" MODIFIED_BY="[Empty name]" NAME="Paulussen 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-12-01 16:16:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paulussen M, Ahrens S, Braun-Munzinger G, Craft AW, Dockhorn-Dworniczak B, Dörffel W, et al</AU>
<TI>EICESS 92 (European Intergroup Cooperative Ewing's Sarcoma Study) - preliminary results</TI>
<SO>Klinische Padiatrie</SO>
<YR>1999</YR>
<VL>211</VL>
<NO>4</NO>
<PG>276-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paulussen-2001a" MODIFIED="2009-08-25 09:51:44 +0200" MODIFIED_BY="[Empty name]" NAME="Paulussen 2001a" YEAR="2001">
<REFERENCE MODIFIED="2009-08-24 12:50:58 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, et al</AU>
<TI>Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study</TI>
<SO>Annals of Oncology</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>11</NO>
<PG>1619-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paulussen-2008" MODIFIED="2012-10-03 10:32:20 +0200" MODIFIED_BY="[Empty name]" NAME="Paulussen 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-10-03 10:32:20 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paulussen M, Craft AW, Lewis I, Hackshaw A, Douglas C, Dunst J, et al</AU>
<TI>Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment-cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>27</NO>
<PG>4385-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ridola-2009" MODIFIED="2009-11-25 14:27:30 +0100" MODIFIED_BY="Jenny Bellorini" NAME="Ridola 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-25 14:27:30 +0100" MODIFIED_BY="Jenny Bellorini" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ridola V, Fawaz O, Aubier F, Bergeron C, de Vathaire F, Pichon F, et al</AU>
<TI>Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens</TI>
<SO>European Journal of Cancer</SO>
<YR>2009</YR>
<VL>45</VL>
<NO>5</NO>
<PG>814-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stevens-2005" MODIFIED="2009-12-01 16:16:36 +0100" MODIFIED_BY="[Empty name]" NAME="Stevens 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-12-01 16:16:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stevens MC, Rey A, Bouvet N, Ellershaw C, Flamant F, Habrand JL, et al</AU>
<TI>Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>12</NO>
<PG>2618-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-den-Berg-2013" MODIFIED="2015-06-18 16:11:44 +0200" MODIFIED_BY="[Empty name]" NAME="van den Berg 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-06-18 16:11:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van den Berg H, Paulussen M, Gaspar N, Lewis I, Dirksen U, Brennan B, et al</AU>
<TI>Impact of gender on efficacy and acute toxicity in standard risk localized (SR) Ewing sarcomas (ES) in the Euro-Ewing99-R1 trial</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2013</YR>
<VL>31</VL>
<NO>15 Suppl</NO>
<PG>10031</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winkler-1988" MODIFIED="2009-08-24 13:13:57 +0200" MODIFIED_BY="[Empty name]" NAME="Winkler 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-08-24 13:13:55 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, et al</AU>
<TI>Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1988</YR>
<VL>6</VL>
<NO>2</NO>
<PG>329-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-09-29 15:17:31 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-09-29 15:17:31 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Burke-1999" MODIFIED="2009-08-25 10:32:47 +0200" MODIFIED_BY="[Empty name]" NAME="Burke 1999" TYPE="JOURNAL_ARTICLE">
<AU>Burke GA, Estlin EJ, Lowis SP</AU>
<TI>The role of pharmacokinetic and pharmacodynamic studies in the planning of protocols for the treatment of childhood cancer</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>1999</YR>
<VL>25</VL>
<PG>13-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carli-2003" MODIFIED="2009-12-01 16:21:28 +0100" MODIFIED_BY="[Empty name]" NAME="Carli 2003" TYPE="JOURNAL_ARTICLE">
<AU>Carli M, Passone E, Perilongo G, Bisogno G</AU>
<TI>Ifosfamide in pediatric solid tumors</TI>
<SO>Oncology</SO>
<YR>2003</YR>
<VL>65</VL>
<NO>Suppl 2</NO>
<PG>99-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fawaz-2005" MODIFIED="2009-12-01 16:21:47 +0100" MODIFIED_BY="[Empty name]" NAME="Fawaz 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fawaz O, Ridola V, Schmitt C, Gentet JC, Aubier F, Orbach D, et al</AU>
<TI>Ifosfamide vs. cyclophosphamide: long term gonadal effects in male survivors of childhood cancer</TI>
<SO>Sarcoma</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GCCR-2004" MODIFIED="2009-12-01 16:21:56 +0100" MODIFIED_BY="[Empty name]" NAME="GCCR 2004" TYPE="OTHER">
<TI>German Childhood Cancer Registry: Annual Report 2004</TI>
<SO>http://www.kinderkrebsregister.de/texte04pdf/6_22.pdf (accessed 15 December 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-GCCR-2004-appendix" MODIFIED="2009-12-01 16:22:04 +0100" MODIFIED_BY="[Empty name]" NAME="GCCR 2004 appendix" TYPE="OTHER">
<TI>German Childhood Cancer Registry: Annual Report 2004 Appendix</TI>
<SO>http://www.kinderkrebsregister.de/texte04pdf/taba1te2.pdf (accessed 15 December 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groninger-2004" MODIFIED="2009-08-25 10:39:30 +0200" MODIFIED_BY="[Empty name]" NAME="Groninger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Groninger E, Proost JH, De Graaf SSN</AU>
<TI>Pharmacokinetic studies in children with cancer</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2004</YR>
<VL>52</VL>
<PG>173-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2015-09-29 15:17:31 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins J, Green S (eds)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Collaboration 2005</TI>
<SO>http://www.cochrane.org/resources/handbook/hbook.htm</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-12-01 16:22:33 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Howell-2001" MODIFIED="2009-08-25 12:20:44 +0200" MODIFIED_BY="[Empty name]" NAME="Howell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Howell SJ, Shalet SM</AU>
<TI>Testicular function following chemotherapy</TI>
<SO>Human Reproduction Update</SO>
<YR>2001</YR>
<VL>7</VL>
<PG>363-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kasper-2005" MODIFIED="2009-08-25 12:20:51 +0200" MODIFIED_BY="[Empty name]" NAME="Kasper 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kasper B, Ho AD, Egerer G</AU>
<TI>Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?</TI>
<SO>Oncology</SO>
<YR>2005</YR>
<VL>68</VL>
<PG>115-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knijnenburg-2013" MODIFIED="2015-08-24 14:32:21 +0200" MODIFIED_BY="[Empty name]" NAME="Knijnenburg 2013" TYPE="COCHRANE_REVIEW">
<AU>Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AYN, Bökenkamp A, Blufpand H, vanDulmen-den Broeder E, et al</AU>
<TI>Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>10</NO>
<IDENTIFIERS MODIFIED="2015-08-24 14:32:13 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-08-24 14:32:13 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008944.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lai-2005" MODIFIED="2009-08-25 12:21:08 +0200" MODIFIED_BY="[Empty name]" NAME="Lai 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lai KN, Tang SC, Mok CC</AU>
<TI>Treatment for lupus nephritis: a revisit</TI>
<SO>Nephrology (Carlton)</SO>
<YR>2005</YR>
<VL>10</VL>
<PG>180-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paulussen-2001" MODIFIED="2009-08-25 12:21:31 +0200" MODIFIED_BY="[Empty name]" NAME="Paulussen 2001" TYPE="JOURNAL_ARTICLE">
<AU>Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al</AU>
<TI>Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2001</YR>
<VL>19</VL>
<PG>1818-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raney-1994" MODIFIED="2009-12-01 16:23:01 +0100" MODIFIED_BY="[Empty name]" NAME="Raney 1994" TYPE="JOURNAL_ARTICLE">
<AU>Raney B, Ensign LG, Foreman J, Khan F, Newton W, Ortega J, et al</AU>
<TI>Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor</TI>
<SO>American Journal of Pediatric Hematology/Oncology</SO>
<YR>1994</YR>
<VL>16</VL>
<PG>286-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossi-1999" MODIFIED="2009-08-25 12:22:01 +0200" MODIFIED_BY="[Empty name]" NAME="Rossi 1999" TYPE="JOURNAL_ARTICLE">
<AU>Rossi R, Kleta R, Ehrich JH</AU>
<TI>Renal involvement in children with malignancies</TI>
<SO>Pediatric Nephrology</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>153-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-1990" MODIFIED="2009-08-25 12:22:32 +0200" MODIFIED_BY="[Empty name]" NAME="Shaw 1990" TYPE="JOURNAL_ARTICLE">
<AU>Shaw PJ, Eden T</AU>
<TI>Ifosfamide in paediatric oncology: tried but not tested?</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>335</VL>
<PG>1022-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simbre-2005" NAME="Simbre 2005" TYPE="JOURNAL_ARTICLE">
<AU>Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE</AU>
<TI>Cardiotoxicity of cancer chemotherapy: implications for children</TI>
<SO>Paediatric Drugs</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>187-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skinner-2003" MODIFIED="2009-08-25 12:22:54 +0200" MODIFIED_BY="[Empty name]" NAME="Skinner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Skinner R</AU>
<TI>Chronic ifosfamide nephrotoxicity in children</TI>
<SO>Medical and Pediatric Oncology</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>190-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spunt-2004" MODIFIED="2009-08-25 12:23:06 +0200" MODIFIED_BY="[Empty name]" NAME="Spunt 2004" TYPE="JOURNAL_ARTICLE">
<AU>Spunt SL, Smith LM, Ruymann FB, Qualman SJ, Donaldson SS, Rodeberg DA, et al</AU>
<TI>Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group</TI>
<SO>Clinical Cancer Research</SO>
<YR>2004</YR>
<VL>10</VL>
<PG>6072-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-St_x00f6_hr-2007" MODIFIED="2009-08-25 12:25:38 +0200" MODIFIED_BY="[Empty name]" NAME="Stöhr 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stöhr W, Patzer L, Paulides M, Kremers A, Beck JD, Langer T, et al</AU>
<TI>Growth impairment after ifosfamide-induced nephrotoxicity in children</TI>
<SO>Pediatric Blood and Cancer</SO>
<YR>2007</YR>
<VL>48</VL>
<PG>571-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Berg-2002" MODIFIED="2009-08-25 10:29:47 +0200" MODIFIED_BY="[Empty name]" NAME="Van den Berg 2002" TYPE="JOURNAL_ARTICLE">
<AU>Van den Berg H</AU>
<TI>Biology and therapy of malignant solid tumors in childhood</TI>
<SO>Cancer Chemotherapy and Biological Response Modifiers</SO>
<YR>2002</YR>
<VL>20</VL>
<PG>605-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weller-2005" MODIFIED="2009-08-25 12:23:29 +0200" MODIFIED_BY="[Empty name]" NAME="Weller 2005" TYPE="JOURNAL_ARTICLE">
<AU>Weller F, Huppertz HI</AU>
<TI>The treatment of juvenile rheumatism: pharmacotherapy</TI>
<TO>Die Behandlung des kindlichen Rheumas: Pharmakotherapie</TO>
<SO>Zeitschrift fur Rheumatologie</SO>
<YR>2005</YR>
<VL>64</VL>
<PG>308-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2005" MODIFIED="2009-08-25 12:24:16 +0200" MODIFIED_BY="[Empty name]" NAME="Zhang 2005" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J, Tian Q, Chan SY, Duan W, Zhou S</AU>
<TI>Insights into oxazaphosphorine resistance and possible approaches to its circumvention</TI>
<SO>Drug Resistance Updates</SO>
<YR>2005</YR>
<VL>8</VL>
<PG>271-97</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-06-08 16:07:47 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Mulder-2010" MODIFIED="2015-06-08 16:07:34 +0200" MODIFIED_BY="[Empty name]" NAME="Mulder 2010" TYPE="COCHRANE_REVIEW">
<AU>Mulder RL, Paulides M, Langer T, Kremer LCM, van Dalen EC</AU>
<TI>Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-10-03 10:34:11 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-03 10:34:11 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006300.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mulder-2012" MODIFIED="2015-06-08 16:07:47 +0200" MODIFIED_BY="[Empty name]" NAME="Mulder 2012" TYPE="COCHRANE_REVIEW">
<AU>Mulder RL, Paulides M, Langer T, Kremer LCM, van Dalen EC</AU>
<TI>Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2015-06-08 16:07:16 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-06-08 16:07:16 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006300"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Paulides-2006" MODIFIED="2012-10-03 10:34:43 +0200" MODIFIED_BY="[Empty name]" NAME="Paulides 2006" TYPE="COCHRANE_PROTOCOL">
<AU>Paulides M, Stöhr W, Langer T, Kremer LCM, van Dalen EC</AU>
<TI>Cyclophosphamide versus ifosfamide for paediatric and young adult sarcoma patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4. Art. No.: CD006300</NO>
<IDENTIFIERS MODIFIED="2012-10-03 10:34:38 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-03 10:34:38 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006300"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-09-29 15:16:28 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-09-29 15:16:28 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:09:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baker-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:09:21 +0100" MODIFIED_BY="[Empty name]">
<P>Preliminary results of <LINK REF="STD-Crist-2001" TYPE="STUDY">Crist 2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:09:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bramwell-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:09:23 +0100" MODIFIED_BY="[Empty name]">
<P>Preliminary results of <LINK REF="STD-Bramwell-1987" TYPE="STUDY">Bramwell 1987</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:09:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bramwell-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:09:30 +0100" MODIFIED_BY="[Empty name]">
<P>Included patients aged 30 years or older; no separate data on patients less than 30 years of age</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:09:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bramwell-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:09:32 +0100" MODIFIED_BY="[Empty name]">
<P>Same study as <LINK REF="STD-Bramwell-1986" TYPE="STUDY">Bramwell 1986</LINK> and <LINK REF="STD-Bramwell-1987" TYPE="STUDY">Bramwell 1987</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:09:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crist-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:09:33 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceeding of <LINK REF="STD-Crist-2001" TYPE="STUDY">Crist 2001</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:09:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crist-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:09:35 +0100" MODIFIED_BY="[Empty name]">
<P>All patients received cyclophosphamide during continuation therapy; no data until continuation therapy presented separately for both treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-24 14:39:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dirksen-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-24 14:39:42 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received ifosfamide during induction therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-24 14:39:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dirksen-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-24 14:39:44 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received ifosfamide during induction therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-29 15:16:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunst-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-29 15:16:23 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation of participants to cyclophosphamide versus ifosfamide; historical controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-29 15:16:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gaspar-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-29 15:16:25 +0200" MODIFIED_BY="[Empty name]">
<P>Not an RCT/CCT; all patients received cyclophosphamide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-24 14:41:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gupta-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-24 14:41:06 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received cyclophosphamide during continuation therapy; no survival data until continuation therapy presented separately for both treatment groups</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:10:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jurgens-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:10:27 +0100" MODIFIED_BY="[Empty name]">
<P>Conference proceeding of <LINK REF="STD-Paulussen-2001a" TYPE="STUDY">Paulussen 2001a</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-06-18 16:05:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Deley-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-06-18 16:05:29 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received ifosfamide during induction therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:10:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paulussen-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:10:27 +0100" MODIFIED_BY="[Empty name]">
<P>Same study as <LINK REF="STD-Paulussen-2001a" TYPE="STUDY">Paulussen 2001a</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:10:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paulussen-2001a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:10:32 +0100" MODIFIED_BY="[Empty name]">
<P>Included patients aged 30 years or older; no separate data on patients less than 30 years of age; all patients received ifosfamide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-03 10:31:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paulussen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-03 10:31:16 +0200" MODIFIED_BY="[Empty name]">
<P>Same study as <LINK REF="STD-Paulussen-2001a" TYPE="STUDY">Paulussen 2001a</LINK>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-01 16:10:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ridola-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-01 16:10:34 +0100" MODIFIED_BY="[Empty name]">
<P>Historical controls; other chemotherapy not the same in both treatment groups; no data on only sarcoma patients; primary outcome not described</P>
<P>Also presented as a conference proceeding (<LINK REF="REF-Fawaz-2005" TYPE="REFERENCE">Fawaz 2005</LINK>)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-29 15:16:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stevens-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-29 15:16:26 +0200" MODIFIED_BY="[Empty name]">
<P>Not an RCT/CCT; none of the patients received cyclophosphamide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-08-24 14:39:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-den-Berg-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-08-24 14:39:50 +0200" MODIFIED_BY="[Empty name]">
<P>All patients received ifosfamide during induction therapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-09-29 15:16:28 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Winkler-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-09-29 15:16:28 +0200" MODIFIED_BY="[Empty name]">
<P>No randomisation of participants to cyclophosphamide versus ifosfamide</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial; CCT: controlled clinical trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-08-24 14:40:44 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-09-13 14:54:52 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-04-28 09:56:16 +0200" MODIFIED_BY="[Empty name]">Search strategy for Cochrane Central Register of Controlled Trials (CENTRAL)</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-25 13:23:37 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>ifosfamide</B> the following subject headings and text words were used:</P>
<P>(ifosfamide OR iphosphamide OR iso-endoxan OR iso endoxan OR isophosphamide OR isofosfamide OR holoxan OR asta z 4942 OR NSC-109,724 OR NSC 109,724 OR NSC109,724 OR NSC 109724 OR NSC-109724 OR NSC109724 OR cyclic p-oxides OR ethylamines OR oxazines OR ifosfa* OR iphospha* OR isofosfa* OR isophospha*) in Clinical Trials</P>
<P>(2) For <B>cyclophosphamide</B> the following subject headings and text words were used:</P>
<P>(cyclophosphamide OR cyclophosphane OR cytophosphan OR B-518 OR cyclophosphamide monohydrate OR endoxan OR cytoxan OR neosar OR procytox OR sendoxan OR NSC-26271 OR NSC 26271 OR NSC26271 OR endox* OR cyclophospha*) in Clinical Trials</P>
<P>(3) For <B>sarcoma</B> the following subject headings and text words were used:</P>
<P>(sarcoma OR sarcomas OR soft tissue sarcoma OR soft tissue sarcomas OR epithelioid sarcoma OR epithelioid sarcomas OR spindle cell sarcoma OR spindle cell sarcomas OR sarcom* OR adenosarcoma OR adenosarcom* OR carcinosarcoma OR carcinosarcom* OR chondrosarcoma OR chondrosarcom* OR fibrosarcoma OR fibrosarcom* OR dermatofibrosarcoma OR dermatofibrosarcom* OR neurofibrosarcoma OR neurofibosarcom* OR neurogenic sarcoma OR hemangiosarcoma OR hemangiosarcom* OR haemangiosarcom* OR angiosarcoma OR angiosarcom* OR leiomyosarcoma OR leiomyosarcom* OR liposarcoma OR liposarcom* OR lymphangiosarcoma OR lymphangiosarcom* OR myxosarcoma OR myxosarcom* OR synovial sarcoma OR sarcoma synovial OR small cell sarcoma OR granulocytic sarcoma OR alveolar soft part sarcoma OR clear cell sarcoma OR osteosarcoma OR osteosarcomas OR osteosarcom* OR osteogenic sarcoma OR osteogenic sarcomas OR juxtacortical osteosarcoma OR juxtacortical osteosarcomas OR rhabdomyosarcoma OR rhabdomyosarcomas OR rhabdomyosarcom* OR myosarcoma OR myosarcomas OR myosarcom* OR embryonal rhabdomyosarcoma OR embryonal rhabdomyosarcomas OR alveolar rhabdomyosarcoma OR alveolar rhabdomyosarcomas OR ewing's sarcoma OR ewing tumor OR ewing tumors OR ewing's tumor OR tumor ewing's OR ewing*) in Clinical Trials</P>
<P>
<B>The different searches were combined as (1) AND (2) AND (3).</B>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-08-24 14:40:38 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-11-25 14:32:28 +0100" MODIFIED_BY="Jenny Bellorini">Search strategy for MEDLINE/PubMed</TITLE>
<APPENDIX_BODY MODIFIED="2015-08-24 14:40:38 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>ifosfamide</B> the following subject headings and text words were used:<BR/>ifosfamide OR iphosphamide OR iso-endoxan OR iso endoxan OR isophosphamide OR isofosfamide OR holoxan OR asta z 4942 OR NSC-109,724 OR NSC 109,724 OR NSC109,724 OR NSC 109724 OR NSC-109724 OR NSC109724 OR cyclic p-oxides OR ethylamines OR oxazines OR ifosfa* OR iphospha* OR isofosfa* OR isophospha*</P>
<P>(2) For <B>cyclophosphamide</B> the following subject headings and text words were used:<BR/>cyclophosphamide OR cyclophosphane OR cytophosphan OR B-518 OR cyclophosphamide monohydrate OR monohydrate, cyclophosphamide OR endoxan OR cytoxan OR neosar OR procytox OR sendoxan OR NSC-26271 OR NSC 26271 OR NSC26271 OR cyclophosphamide, (R)-isomer OR cyclophosphamide, (S)-isomer OR cyclophosphamide, (+)-isomer OR endox* OR cyclophospha*</P>
<P>(3) For <B>sarcoma</B> the following subject headings and text words were used:<BR/>sarcoma OR sarcomas OR sarcoma, soft tissue OR sarcomas, soft tissue OR soft tissue sarcoma OR soft tissue sarcomas OR sarcoma, epithelioid OR epithelioid sarcoma OR epithelioid sarcomas OR sarcomas, epithelioid OR sarcoma, spindle cell OR sarcomas, spindle cell OR spindle cell sarcoma OR spindle cell sarcomas OR sarcom* OR adenosarcoma OR adenosarcom* OR carcinosarcoma OR carcinosarcom* OR chondrosarcoma OR chondrosarcom* OR fibrosarcoma OR fibrosarcom* OR dermatofibrosarcoma OR dermatofibrosarcom* OR neurofibrosarcoma OR neurofibosarcom* OR neurogenic sarcoma OR hemangiosarcoma OR hemangiosarcom* OR haemangiosarcom* OR angiosarcoma OR angiosarcom* OR leiomyosarcoma OR leiomyosarcom* OR liposarcoma OR liposarcom* OR lymphangiosarcoma OR lymphangiosarcom* OR myxosarcoma OR myxosarcom* OR synovial sarcoma OR sarcoma synovial OR sarcoma, small cell OR small cell sarcoma OR sarcoma, granulocytic OR granulocytic sarcoma OR sarcoma, alveolar soft part OR alveolar soft part sarcoma OR sarcoma, clear cell OR clear cell sarcoma OR osteosarcoma OR osteosarcomas OR osteosarcom* OR osteogenic sarcoma OR osteogenic sarcomas OR sarcoma, osteogenic OR sarcomas, osteogenic OR osteosarcoma, juxtacortical OR osteosarcomas, juxtacortical OR juxtacortical osteosarcoma OR juxtacortical osteosarcomas OR rhabdomyosarcoma OR rhabdomyosarcomas OR rhabdomyosarcom* OR myosarcoma OR myosarcomas OR myosarcom* OR embryonal rhabdomyosarcoma OR embryonal rhabdomyosarcomas OR rhabdomyosarcomas, embryonal OR alveolar rhabdomyosarcoma OR alveolar rhabdomyosarcomas OR rhabdomyosarcomas, alveolar OR sarcoma, ewing's OR ewing's sarcoma OR sarcoma, ewing OR sarcoma, ewings OR ewing tumor OR ewing tumors OR ewing's tumor OR tumor ewing's OR ewing*</P>
<P>
<B>The different searches were combined as (1) and (2) and (3) and the highly sensitive search strategy for RCTs and CCTs</B> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK> (September 2006) / <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK> (November 2008 when updating the original search and March 2012 and March 2015 for the review updates)).</P>
<P>(RCT: randomised controlled trial; CCT: controlled clinical trial).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-08-24 14:40:44 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2009-11-25 14:32:47 +0100" MODIFIED_BY="Jenny Bellorini">Search strategy for EMBASE/Ovid</TITLE>
<APPENDIX_BODY MODIFIED="2015-08-24 14:40:44 +0200" MODIFIED_BY="[Empty name]">
<P>(1) For <B>cyclophosphamide</B> the following subject headings and text words were used:</P>
<P>((cyclophosphamide or cyclophosphane or cytophosphan or B-518 or cyclophosphamide monohydrate or endoxan or cytoxan or neosar or procytox or sendoxan or NSC-26271 or NSC 26271 or NSC26271 or endox$ or cyclophospha$ or cyclofosfa$).mp) or cyclophosphamide/ or cyclophosphamide derivative/ or 50-18-0.rn<BR/>
</P>
<P>(2) For <B>ifosfamide</B> the following subject headings and text words were used:</P>
<P>((ifosfamide or iphosphamide or iso-endoxan or iso endoxan or isophosphamide or isofosfamide or holoxan or asta z 4942 or NSC-109,724 or NSC 109,724 or NSC109,724 or NSC 109724 or NSC-109724 or NSC109724 or cyclic p-oxides or ethylamines or oxazines or ifosfa$ or iphospha$ or isofosfa$ or isophospha$).mp) or ifosfamide/ or 3778-73-2.rn<BR/>
</P>
<P>(3) For <B>sarcoma</B> the following subject headings and text words were used:</P>
<P>((sarcoma or sarcomas or soft tissue sarcoma or soft tissue sarcomas or epithelioid sarcoma or epithelioid sarcomas or spindle cell sarcoma or spindle cell sarcomas or sarcom$ or adenosarcoma or adenosarcom$ or carcinosarcoma or carcinosarcom$ or chondrosarcoma or chondrosarcom$ or fibrosarcoma or fibrosarcom$ or dermatofibrosarcoma or dermatofibrosarcom$ or neurofibrosarcoma or neurofibosarcom$ or neurogenic sarcoma or hemangiosarcoma or hemangiosarcom$ or haemangiosarcoma or haemangiosarcom$ or angiosarcoma or angiosarcom$ or leiomyosarcoma or leiomyosarcom$ or liposarcoma or liposarcom$ or lymphangiosarcoma or lymphangiosarcom$ or myxosarcoma or myxosarcom$ or synovial sarcoma or small cell sarcoma or granulocytic sarcoma or alveolar soft part sarcoma or clear cell sarcoma or osteosarcoma or osteosarcomas or osteosarcom$ or osteogenic sarcoma or osteogenic sarcomas or juxtacortical osteosarcoma or juxtacortical osteosarcomas or rhabdomyosarcoma or rhabdomyosarcomas or rhabdomyosarcom$ or myosarcoma or myosarcomas or myosarcom$ or embryonal rhabdomyosarcoma or embryonal rhabdomyosarcomas or alveolar rhabdomyosarcoma or alveolar rhabdomyosarcomas or ewing's sarcoma or ewings sarcoma or ewing tumor or ewing tumors or ewing's tumor or ewing$).mp) or ((bone sarcoma or soft part sarcoma or chondroblastic sarcoma).mp) or soft tissue sarcoma/ or ewing sarcoma/ or sarcoma/ or epithelioid sarcoma/ or spindle cell sarcoma/ or adenosarcoma/ or carcinosarcoma/ or chondrosarcoma/ or fibrosarcoma or dermatofibrosarcoma protuberans/ or neurofibrosarcoma/ or angiosarcoma/ or liposarcoma/ or leiomyosarcoma/ or lymphangiosarcoma/ or myxosarcoma/ or synovial sarcoma/ or small cell sarcoma/ or granulocytic sarcoma/ or alveolar soft part sarcoma/ or clear cell sarcoma/ or osteosarcoma/ or juxtacortical osteosarcoma/ or rhabdomyosarcoma/ or embryonal rhabdomyosarcoma/ or myosarcoma/<BR/>
</P>
<P>(4) For <B>RCTs and CCTs</B> the following subject headings and text words were used (based on the highly sensitive search strategy for RCTs and CCTs of <LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>):</P>
<P>(a) clinical trial/ or controlled study/ or randomized controlled trial/ or double blind procedure/ or single blind procedure/ or comparative study/ or randomization/ or prospective study/ or placebo/ or phase 2 clinical trial/ or phase 3 clinical study.mp or phase 4 clinical study.mp or phase 3 clinical trial/ or phase 4 clinical trial/ or allocat$.mp or blind$.mp or control$.mp or placebo$.mp or prospectiv$.mp or random$.mp or ((singl$ or doubl$ or trebl$ or tripl$) and (blind$ or mask$)).mp or (versus or vs).mp or (randomized controlled trial$ or randomised controlled trial$).mp or controlled clinical trial$.mp or clinical trial$.mp<BR/>(b) human/ or nonhuman/ or animal/ or animal experiment/<BR/>(c) (b) NOT human/<BR/>(d) (a) NOT (c)<BR/>
</P>
<P>When updating the original search in November 2008 and in March 2012 and 2015 we used the following search based on the highly sensitive search strategy for RCTs and CCTs of <LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>:</P>
<P>(a) randomized controlled trial or controlled clinical trial).mp or (randomized or placebo or randomly or trial or groups).ti,ab or drug therapy.sh<BR/>(b) limit (a) to human</P>
<P>
<B>The different searches were combined as (1) AND (2) AND (3) AND (4).</B>
</P>
<P>mp: title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name; ti,ab: title, abstract; sh: subject heading; rn: chemical abstract services registration number; RCT: randomized controlled trial; CCT: controlled clinical trial</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>